Maxim Group initiated coverage on Rani Therapeutics with a new price target
$RANI
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $15.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/2/2024 | $17.00 | Outperform | Oppenheimer |
| 6/14/2024 | $15.00 | Buy | Maxim Group |
| 6/13/2024 | $10.00 | Buy | Rodman & Renshaw |
| 4/17/2023 | $24.00 | Buy | BTIG Research |
| 10/11/2022 | $15.00 | Buy | UBS |
| 7/27/2022 | $22.00 | Buy | H.C. Wainwright |
| 6/13/2022 | $28.00 | Outperform | Wedbush |
| 8/25/2021 | $24.00 | Buy | BTIG |
SCHEDULE 13G - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
SCHEDULE 13G - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
Oppenheimer initiated coverage of Rani Therapeutics with a rating of Outperform and set a new price target of $17.00
Maxim Group initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $10.00
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy. Mr. Høiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including extensive expertise in obesity and metabolic disease. "Jesper is a highly respected leader with a rare combination of strategic insight and deep commercial experience, and we are thrilled to welcome him as Head of Strategy," said Talat Imr
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025 and provide a business update on Thursday, March 26, 2026 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 26, 2026. Individuals interested in listen
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. "We are thrilled to announce Alireza's promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity," said Talat Imran, Chief Executive Officer of Rani Therapeutics. "His technical and operational leadership experience in the medical device and life s
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy. Mr. Høiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including extensive expertise in obesity and metabolic disease. "Jesper is a highly respected leader with a rare combination of strategic insight and deep commercial experience, and we are thrilled to welcome him as Head of Strategy," said Talat Imr
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – – Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors – – Cash runway expected to extend into 2028 – SAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Abraham ("Abe") Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. In conjunction with the new appointments, Andrew Farquharson and Maulik Nanavaty have stepped down from the Board of Directors. "We are thrilled to welcome Abe and Vasudev to our Board of Directors as we enter an exciting new era for Rani, highlighted by both our clinical-stage pipeline and expansion opportunities into high-value therapeutics from our rece
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025 and provide a business update on Thursday, March 26, 2026 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 26, 2026. Individuals interested in listen
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 - - Conference call today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeut
SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 31, 2025. Individuals interested in listenin
SC 13G - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)